Lorus Takes Leukemia Drug to Phase II
Posted on: Thursday, 30 August 2007, 12:21 CDT
Lorus Therapeutics is advancing its investigational acute myeloid leukemia drug to Phase II trials after reporting encouraging results from a proof of concept study.
The proof of concept clinical trial demonstrated safety and appropriate dosing of the combination regimen and showed promising clinical responses in patients under 60 years of age. Complete results from the clinical trial are expected to be presented by the investigators in a scientific publication.
The advanced phase II clinical trial, which is now underway, includes both an efficacy study and a novel additional study to measure intracellular target activities and pharmacological synergies between the two agents. In the first stage of the 60 patient trial, the pharmacologic and target related activity of GTI-2040 and high dose Ara-C (HiDAC) will be evaluated in two groups, to determine the contribution of each agent alone and in combination.
Ara-C, including HiDAC, is a key component of nearly all AML regimens, for induction, consolidation or salvage treatment. However even with intensification of the Ara-C, response to treatment in refractory and relapsed disease is limited by development of increasing resistance to Ara-C with repeated exposures.
The second stage of the trial will provide efficacy evaluation in a larger patient population. Canadian biopharmaceutical firm Lorus expects the clinical trial to be completed by the end of 2008.
Source: Datamonitor
Related Articles
- QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
- AGI Therapeutics Plc Announces Key Findings of Clinical PK Study of Arbaclofen (AGI-006)
- Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- Next Generation Nasal Spray Against Influenza: Clinical Phase I Study Started With FLUVACCdelNS1
- Mitralign Announces an Additional Medical Director in Advance of Clinical Pilot Study
- ANA975 in a New 13-Week Pre-Clinical Toxicology Study Using Crystalline Form
- SD Pharmaceuticals Completes Pivotal Pre-Clinical Efficacy Study on Its Novel and Less Toxic Docetaxel Formulation
- Samaritan Kicks Off Second HIV Phase II Monotherapy Trial to Further Study Oral HIV Entry Inhibitor Drug SP-01A
- Clinical Case Study Shows GE Healthcare's LightSpeed VCT Only CT Scanner Capable of Imaging the Heart in As Few As Five Beats; Major Clinical Studies in Progress to Compare LightSpeed VCT Scan To Catheterization
- Pre-Clinical Toxicity Studies Show Quigley Pharma's Diabetic Neuropathy Formulation QR-333 is Safe for Topical Application
 |
 |
User Comments (0)
RSS Feeds